Reporting snapshot · 1 November 2026 (Asia/Karachi). The register is still being filled and the consumer-facing launch has not happened: the project is expected to be opened formally by the prime minister by the end of November, and no scanable pack or public register has been published. The main limitation is that the 15 products named by the Sindh laboratory are known only from the laboratory's letter as carried in the press, and neither the Drug Regulatory Authority of Pakistan nor the Sindh Quality Control Board has published a response.
What the register now contains
Federal Health Minister Mustafa Kamal said on 1 November that the Drug Regulatory Authority of Pakistan (DRAP) has been made “fully transparent and digitalized”, speaking to industrialists at the Korangi Association of Trade and Industry in Karachi, Radio Pakistan reported.
He said more than 86,000 medicines made by the pharmaceutical industry have been registered under the Track and Trace System, which lets a consumer scan a medicine with a mobile phone and check its authenticity, and that companies can now register their medicines and products online. The Express Tribune reported the same remarks from the same event, adding that barcodes have been introduced for 86,000 branded products manufactured by 650 pharmaceutical companies and that the ministry’s database now holds information on 86,000 medicines.
The same report described the reason for the shift in administrative terms: companies previously had to pay “hefty bribes” to register medicines with DRAP, while under the new system every document is processed automatically.
The announcement is the implementation stage of a decision the federal cabinet took on 2 June 2026, when it approved a nationwide track-and-trace system with standardised 2D barcodes and serialisation data on medicine packaging under DRAP’s supervision, as KhabarWire reported at the time. What is new in November is not the decision but its scale: the first published count of registered products, and a named launch date for the part shoppers are meant to notice.
What a shopper can actually check
The mechanics were put to the National Assembly on 30 October, when the health minister said the project would be formally launched by the prime minister by the end of November, Radio Pakistan reported.
Under that plan, a shopper scans the 2D barcode on a pack with a mobile phone at the pharmacy and can establish whether the medicine is genuine, whether the price being charged is the approved price, and what the expiry date is. The same briefing said the underlying data would let DRAP take action against those involved in the manufacture and distribution of counterfeits.
For a buyer at a counter, that is the practical change the register is meant to deliver: a check performed with a phone camera rather than an assurance from the person dispensing the medicine. For the regulator, it is the difference between a list of approved products and a trail, because a serialised pack can in principle be tied back to a batch, an importer and a distributor. Whether the trail is complete depends on how many of the packs actually on sale carry the code, which the government has not yet published.
The first laboratory results
The register is not the only thing that moved this week. Laboratory testing in Karachi has failed 15 pharmaceutical products sold at medical stores, The Express Tribune reported.
Syed Adnan Rizvi, director of the Sindh Drug Testing Laboratory, said drug inspectors had collected 15 samples from medical stores in Karachi’s south and central districts and sent them for chemical examination. He said all 15 were found to be substandard and counterfeit, with some also unregistered, and that the chemical composition of the products did not match the ingredients declared on their packaging.
The named products include widely used antibiotics, painkillers, eye and ear preparations, mouthwashes and baby-care items. Rizvi listed Baby Eye Care, Tobramycin Ophthalmic Solution, Total Care Mouthwash, Magic Lotion, Anti Plaque Mouthwash, Denziclor Mouthwash, Happy Tooth Kid Mouthwash, Babycare Ear Cream and Vital Ear Cream, together with five medicines: the antibiotics Velosef and Augmentin, the painkiller Nospa Forte, Mucaine syrup and Brexin tablets.
In a letter dated 28 October 2026 and signed by Rizvi, the laboratory declared the products substandard, counterfeit and unregistered under the Drugs Act 1976 and the DRAP Act 2012, and forwarded it to the provincial drug inspector and the secretary of the Sindh Quality Control Board for further action. Rizvi said substandard medicines may fail to produce the desired therapeutic effect and, in some cases, could prove harmful, and he warned that antibiotics whose declared active ingredients are inadequate or absent could leave an infection untreated.
Why it matters
The two developments point in opposite directions, and that is the reason to read them together. A register of 86,000 registered medicines is the first number that makes the country’s pharmaceutical supply chain countable, and it arrives with a stated launch date and a consumer-facing check. The 15 failed products are the first test result showing what happens where the register and the shelf diverge: a pack can be on a shop counter, and can be in someone’s hand as a treatment, without carrying the ingredients it declares.
The antibiotics in that list make the stakes sharper than the mouthwashes. A medicine without its active ingredient is not a smaller version of a working one; it is a different product, sold under a name patients trust, and for an antibiotic it can mean an infection that does not clear. The laboratory’s own letter is the instrument that starts the enforcement chain, and it went to the provincial drug inspector and the Sindh Quality Control Board, not to DRAP’s new digital register.
For the wider fight against counterfeit supply, the register is also the first step that changes the cost of the problem for the consumer. If the approved price and expiry date are visible on a phone, the questions that usually end in a chemist’s word become questions a shopper can settle. KhabarWire has previously reported the enforcement side of the same chain, from the documents that showed DRAP asking the telecom regulator to block websites selling unregistered medicines to the seizure of suspected counterfeit flu vaccine in Lahore. A register that only records what is genuine cannot do that work on its own, which is why the laboratory result matters as much as the product count.
What is still uncertain
Three things are unresolved. The first is what shoppers will actually be able to do on the launch date: the prime minister’s formal opening by the end of November is a plan announced to the National Assembly, not a published application, and no public register or list of scan-ready packs has been released.
The second is the scale of the problem behind the 15 failures. The laboratory sampled 15 products from two districts of Karachi, and the government has published no inspection totals, no seizure figures and no indication of how many products across the country carry a barcode rather than a copycat code. A register of 86,000 registered medicines is also a count of what has been registered, not of what is on shelves.
The third is what happens next to the 15 named products. The laboratory’s letter has gone to the provincial drug inspector and the secretary of the Sindh Quality Control Board, and neither DRAP nor that board has said whether the stocks have been withdrawn, whether any of the products were ever on the track-and-trace register, or what the manufacturers have said. Some of them, on Rizvi’s account, were not registered at all, which places them outside the system the register is meant to police.


